Raab & Moskowitz Asset Management’s Edwards Lifesciences EW Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,845	Closed	-$143K	–	251
2019 Q4	$143K	Buy	+1,845	New	+$144K	0.06%	175
2018 Q4	–	Sell	-1,845	Closed	-$107K	–	262
2018 Q3	$107K	Buy	+1,845	New	+$90.2K	0.04%	195
2015 Q1	–	Sell	-552	Closed	-$12K	–	192
2014 Q4	$12K	Buy	+552	New	+$11.1K	0.01%	311

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Raab & Moskowitz Asset Management's EW Position: Q1 2020 in Review

Raab & Moskowitz Asset Management sold out of Edwards Lifesciences (EW) in Q1 2020, closing a stake of 1,845 shares — an estimated $143K sold.

Raab & Moskowitz Asset Management first reported a position in EW in Q4 2014 and held it in 3 quarters. The position peaked at $143K in Q4 2019. 1,019 funds tracked by Wall St. Rank hold EW as of Q1 2020.

Raab & Moskowitz Asset Management reported no remaining Edwards Lifesciences position as of Q1 2020 after selling out during the quarter.
Raab & Moskowitz Asset Management sold 1,845 Edwards Lifesciences shares in Q1 2020, an estimated $143K.
Raab & Moskowitz Asset Management first reported a position in Edwards Lifesciences in Q4 2014 and held it in 3 quarters.
Raab & Moskowitz Asset Management's Edwards Lifesciences position peaked at $143K in Q4 2019.
1,019 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2020.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2020, filed 14 May 2020.